AgingResearch.NewsJoin free

Sclerostin antibody

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Maryland Stem Cell Research Fund and 6 more
  • Animals1

Outcomes

1

Bone mass

upin mice1

1 study

  1. Sclerostin antibody increases bone mass in mice.

    “treatment with a sclerostin-neutralizing antibody (SclAb), which targets an antagonist of canonical WNT/β-catenin signaling pathway, fully rescues the low bone mass phenotype to wild-type levels.”

    AnimalsZmpste24-/- HGPS mice

    Diminished Canonical β-Catenin Signaling During Osteoblast Differentiation Contributes to Osteopenia in Progeria

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Aug 2018

Latest

Related